Published in

Oxford University Press, Clinical Infectious Diseases, 12(75), p. 2253-2256, 2022

DOI: 10.1093/cid/ciac393

Links

Tools

Export citation

Search in Google Scholar

Cumulative Mycobacterium tuberculosis Infection Incidence (Measured Primarily by Tuberculin Skin Test) Among Infants With Human Immunodeficiency Virus Exposure: Observational Follow-up of an Isoniazid Prophylaxis Trial

Journal article published in 2022 by Sylvia M. LaCourse ORCID, Jaclyn N. Escudero, Jerphason Mecha, A. J. Warr, Barbra A. Richardson, Naziat Carimo, Lisa M. Cranmer, Elizabeth Maleche-Obimbo, Daniel Matemo, John Kinuthia, Thomas R. Hawn, Grace John-Stewart
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract Cumulative 24-month Mycobacterium tuberculosis infection incidence (measured primarily by tuberculin skin test [TST]) was high among human immunodeficiency virus exposed but uninfected infants (8.7 [95% confidence interval, 6.3–11.9] per 100 person-years). Trend for decreased TST positivity among infants at trial end (12 months postenrollment) randomized to isoniazid at 6 weeks of age was not sustained through observational follow-up to 24 months of age. Clinical Trials Registration NCT02613169.